Grammar:		DataElement 5.0
Namespace:		shr.oncology
Description:	"SHR implementation of ASCO requirements."
Uses:  			shr.core, shr.base, shr.finding, shr.action, shr.entity, shr.condition, shr.procedure, shr.adverse, shr.medication

CodeSystem:     SCT = http://snomed.info/sct
CodeSystem:     LNC = http://loinc.org
CodeSystem:		MTH = http://ncimeta.nci.nih.gov
CodeSystem:     UCUM = http://unitsofmeasure.org
CodeSystem:		HGNC = http://www.genenames.org
CodeSystem:		CAP = https://sdt.cap.org
//

EntryElement:	BreastCancer
Concept:		SCT#126926005 "Neoplasm of the breast"
Based on:		Condition  
Description:	"FindingTopic or diagnosis of cancer originating in the tissues of the breast, and potentially spread to other organs of the body."
Value:			CodeableConcept from BreastCancerTypeVS
				Category includes #disease
				ConditionPresenceContext.Stage from BreastCancerStageVS				
				ConditionPresenceContext.Stage.StageDetail value is type BreastCancerTNMStage


EntryElement:	BreastCancerTNMStage
Based on:		EvaluationResult  // maps to FHIR Observation
Concept:		LNC#21908-9
Description:	"The stage of a cancer, assessed according to the standard established by American Joint Committee on Cancer (AJCC). TNM Stage Grouping categorizes the progression of cancer using a modified Roman Numeral system."
Value:			CodeableConcept from BreastCancerStageVS  // could be normative answer group LNC#LL240-3
				FindingCode is LNC#21908-9
1..1			FindingMethod from StagingMethodVS
0..1			StageTimingPrefix from StageTimingPrefixVS
				EvaluationComponent			
includes 0..1 	BreastCancerTStage
includes 0..1 	BreastCancerNStage
includes 0..1 	BreastCancerMStage

		Element:		StageTimingPrefix
		Concept:		TBD
		Description:	"Indicates when the staging was done, in terms of treatment landmarks, either clinical (at diagnosis prior to treatment) (c), pathologic (post-surgical) (p), post-neoadjuvant clinical (yc), or post-neoadjuvant pathologic(yp). The stage timing code is prefix on the N stage. For example, for post-neoadjuvant clinical staging, the N categories are preceded by 'yc' (e.g. ycNX)"
		Value:			CodeableConcept

		Element:		StageSuffix
		Concept:		TBD
		Description:	"Modifies the stage by indicating the size or extent of the cancer or tumor."
		Value:			CodeableConcept		
		
		Element:		BreastCancerTStage
		Concept:		LNC#59528-0
		Based on:		EvaluationComponent
		Description:	"The size and extent of the primary tumor (greatest dimension), based on criteria from the American Joint Committee on Cancer."
		Value:			CodeableConcept from BreastCancerTStageVS

		Element:		BreastCancerNStage
		Concept:		LNC#59525-6
		Based on:		EvaluationComponent
		Description:	"The presence of metastases in regional lymph nodes. The node category for staging is based on criteria from the American Joint Committee on Cancer."
		Value:			CodeableConcept from BreastCancerNStageVS

		Element:		BreastCancerMStage
		Concept:		LNC#59522-3
		Based on:		EvaluationComponent
		Description:	"Part of the TNM classification system representing metastases.  The system is used to describe the spread of cancer to other parts of the body."
		Value:			CodeableConcept from BreastCancerMStageVS

EntryElement:	HistologicGrade
Concept:		MTH#C1511980
Based on:		LaboratoryTestResult
Description:	"The Elston Grade/Nottingham Score, representative of the aggressive potential of the tumor. Well differentiated (Grade 1) look similar to normal cells and are usually slow growing, while poorly differentiated cells (Grade 3) look very different than normal and are fast-growing."
Value:			CodeableConcept from NottinghamCombinedGradeVS
				EvaluationComponent
includes 0..1 	TubuleFormationScore
includes 0..1 	NuclearPleomorphismScore
includes 0..1 	MitoticCountScore

			Element:		TubuleFormationScore
			Concept:		SCT#371470008
			Based on:		EvaluationComponent
			Description:	"A comparison between structures formed by the tumor cells as opposed to those formed by normal cells. Scored 1 to 3 with 3 being the most abnormal."
			Value:			CodeableConcept from TubuleFormationScoreVS  //TODO: Determine if it is better to use codes as opposed to a number 1, 2 or 3. Observations don't support integer or posInteger

			Element:		NuclearPleomorphismScore
			Concept:		TBD
			Based on:		EvaluationComponent
			Description:	"How large and varied the nuclei of the tumor cells are. Scored 1 to 3, with 3 being the most pleomorphism."
			Value:			CodeableConcept from NuclearPleomorphismScoreVS

			Element:		MitoticCountScore
			Concept:		SCT#371472000
			Based on:		EvaluationComponent
			Description:	"How fast the tumor cells are growing and dividing, determined from the number of mitotic cells present. Scored 1 to 3, with 3 being the most mitotic cells."
			Value:			Quantity   // 1 to 3

//			includes 0..1	PercentageInSituCarcinoma   // not sure where this belongs


EntryElement:	BreastCancerBiomarkerPanel
Based on:		LaboratoryTestResult
Concept:		CAP#31159
Description:	"Immunohistochemistry (IHC) assessment for estrogen receptor (ER) and progesterone receptor (PR) as well as IHC or in situ hybridization (ISH) determination of human epidermal growth factor receptor 2 (HER2) status"
Value:			CodeableConcept from BrcaReceptorStatusVS
				FindingCode is CAP#31159
				Members.EvaluationTopic
includes 0..1 	EstrogenReceptorStatus
includes 0..1 	ProgesteroneReceptorStatus
includes 0..1 	HER2ReceptorStatus


EntryElement:	EstrogenReceptorStatus
Based on:		LaboratoryTestResult
Concept:		CAP#31160
Description:	"Estrogen receptor alpha is the predominant estrogen receptor expressed in breast tissue and is overexpressed in around 50% of breast carcinomas. ER status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options."
Value:			CodeableConcept from PositiveNegativeIndeterminateVS
				FindingCode is LNC#16112-5
				FindingMethod is type SpecificLaboratoryTest
0..1			EvaluationComponent
includes 0..1	NuclearPositivity
includes 0..1	AverageStainingIntensity
includes 0..1	StainingControl
includes 0..1	PrimaryAntibody //from EstrogenAntibodyVS if covered
includes 0..1	AllredProportionScore
includes 0..1	AllredIntensityScore
includes 0..1	AllredTotalScore
includes 0..1	OtherReceptorScoringSystem


EntryElement:	ProgesteroneReceptorStatus
Based on:		EvaluationResult
Concept:		LNC#16113-3
Description:	"Progesterone receptor is expressed in 65% of breast carcinomas. PR status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options."
Value:		 	CodeableConcept from PositiveNegativeIndeterminateVS
				FindingCode is LNC#16113-3
				FindingMethod is type SpecificLaboratoryTest
				EvaluationComponent
includes 0..1	NuclearPositivity
includes 0..1	AverageStainingIntensity
includes 0..1	StainingControl
includes 0..1	PrimaryAntibody	// from ProgesteroneAntibodyVS if covered
includes 0..1	AllredProportionScore
includes 0..1	AllredIntensityScore
includes 0..1	AllredTotalScore
includes 0..1	OtherReceptorScoringSystem


EntryElement:	HER2ReceptorStatus
Based on:		EvaluationResult
Concept:		LNC#48676-1
Description:	"HER2 receptor status. HER2 is a member of the human epidermal growth factor receptor family of proteins and is encoded by the ERBB2 oncogene. HER2 is overexpressed in 20-30% of breast tumors,10 and is associated with an aggressive clinical course and poor prognosis. HER2 status (positive=present or overexpressed; negative=absent) is a factor in determining prognosis and treatment options."
Value:		 	CodeableConcept from HER2StatusVS
				FindingCode is LNC#48676-1 "HER2 Interpretation in Tissue"
				FindingMethod is type SpecificLaboratoryTest
				SpecificLaboratoryTest from HER2MethodVS
				Members.EvaluationTopic  // probably not "has member" but "related"
includes 0..1	HER2byImmunohistochemistry
includes 0..1	HER2byInSituHybridization

				
EntryElement:	HER2byImmunohistochemistry
Based on:		EvaluationResult
Concept:		CAP#31163
Description:	"HER2 status as determined by Immunohistochemistry (IHC)"
Value:		 	CodeableConcept from HER2StatusVS
				FindingCode is LNC#72383-3 "HER2 Presence in Tissue by Immunoassay"
				EvaluationComponent
includes 0..1	CompleteMembraneStainingPercent
includes 0..1	PrimaryAntibody  // from HER2AntibodyIHCVS if covered

		Element:		CompleteMembraneStainingPercent
		Based on:		EvaluationComponent
		Concept:		CAP#25884
		Description:	"Percentage of cells with uniform intense complete membrane staining."
		Value:			Quantity with units UCUM#%   // TODO: Percentage causes CLI error
		
EntryElement:	HER2byInSituHybridization
Based on:		EvaluationResult
Concept:		CAP#31166
Description:	"HER2 status as determined by In Situ HybridizationISH."
Value:		 	CodeableConcept from HER2StatusVS
				FindingCode is LNC#72383-3 "HER2 Presence in Tissue by Immunoassay"
				EvaluationComponent
includes 0..1	AverageHER2SignalsPerCell
includes 0..1	AverageCEP17SignalsPerCell
includes 0..1	HER2toCEP17Ratio
includes 0..1	Aneusomy
includes 0..1	HeterogeneousSignals
includes 0..1	PercentageAmplified

		Element:		AverageHER2SignalsPerCell
		Based on:		EvaluationComponent
		Concept:		CAP#25910
		Description:	"Average number of HER2 signals per cell"
		Value:			Quantity
						FindingCode is CAP#25910
		
		Element:		AverageCEP17SignalsPerCell
		Based on:		EvaluationComponent
		Concept:		CAP#25911
		Description:	"Average number CEP17 signals per cell (dual probe only)"
		Value:			Quantity
						FindingCode is CAP#25911
		
		Element:		HER2toCEP17Ratio
		Based on:		EvaluationComponent
		Concept:		LNC#49683-6
		Description:	"HER2 to CEP17 Ratio (dual probe only)"
		Value:			Quantity
						FindingCode is CAP#25912
		
		Element:		Aneusomy
		Based on:		EvaluationComponent
		Concept:		CAP#30478
		Description:	"Aneusomy (as defined by vendor kit used)"
		Value:			CodeableConcept from YesNoVS
						FindingCode is CAP#25912
	
		Element:		HeterogeneousSignals
		Based on:		EvaluationComponent
		Concept:		CAP#30482 
		Description:	"Whether In Situ Hybridization signals were heterogeneous."
		Value:			CodeableConcept from YesNoVS
						FindingCode is CAP#30482
		
		Element:		PercentageAmplified
		Based on:		EvaluationComponent
		Concept:		CAP#31073
		Description:	"Percentage of cells with amplified HER2 signals"
		Value:			Quantity with units UCUM#%
						FindingCode is CAP#31073
	
		Element:		SpecificLaboratoryTest
		Based on:		FindingMethod  // Profiling CodeableConcept!
		Concept:		CAP#31089
		Description:	"The specific test code and additional details. The test name is part of the CodeableConcept."
		0..1			Manufacturer // test vendor
		0..1			ExpirationDate  // if using disposable test supply
		0..1			LotNumber
		0..1			CertifiedBy
		
				Element:	CertifiedBy
				Concept:	TBD
				Description:	"The agency certifying the test."
				Value:		CodeableConcept from CertifiedByVS
				

		Element:		NuclearPositivity
		Based on:		EvaluationComponent
		Concept:		TBD
		Description:	"The percentage of cells that test (stain) positive for the presence of a receptor."
		Value:			Range
		
/*
			Element:		NuclearPositivityPercentage
			Concept:		TBD
			Description:	"The percentage of cells that test (stain) positive for the presence of a receptor."
			Value:			Quantity with units UCUM#%
			
			Element:		NuclearPositivityDecile
			Concept:		TBD
			Description:	"The percentage of cells that test (stain) positive for the presence of a receptor, as a percentage range, 0-10, 11-20, 21-30, etc."
			Value:			CodeableConcept from DecileVS
				
*/

		Element:		PrimaryAntibody
		Based on:		EvaluationComponent
		Concept:		CAP#31092
		Description:	""
		Value:			CodeableConcept
						FindingCode is CAP#31092
		
		Element:		AverageStainingIntensity
		Concept:		CAP#29749
		Based on:		EvaluationComponent
		Description:	"Part of the Allred scoring, based on the intensity of that staining, on a scale of 0 (Negative) to 3 (Strong)."
		Value:			CodeableConcept from StainingIntensityVS
						FindingCode is CAP#29749
		
		Element:		StainingControl
		Based on:		EvaluationComponent
		Concept:		CAP#25895
		Description:	"Whether control cells were present."
		Value:			CodeableConcept from StainingControlVS if covered
						FindingCode is CAP#25895
		
		Element:		AllredProportionScore
		Concept:		CAP#31054
		Based on:		EvaluationComponent
		Description:	"Part of Allred scoring, based on the percentage of cells that stain for a receptor, on a scale of 0 to 5."
		Value:			Quantity with units UCUM#1
						FindingCode is CAP#31054

		Element:		AllredIntensityScore
		Concept:		CAP#29749
		Based on:		EvaluationComponent
		Description:	"Part of the Allred scoring, based on the intensity of that staining, on a scale of 0 to 3."
		Value:			Quantity with units UCUM#1
						FindingCode is CAP#29749
							
		Element:		AllredTotalScore
		Concept:		CAP#31056
		Based on:		EvaluationComponent
		Description:	"The total Allred score, the total of proportion and intensity scores, from 0 to 8."
		Value:			Quantity with units UCUM#1  // unsignedInt -  limit to max of 8
						FindingCode is CAP#31056					

		Element:		OtherReceptorScoringSystem
		Concept:		CAP#31062
		Based on:		EvaluationComponent
		Description:	"A scoring system other than Allred."

		
EntryElement:	OncotypeDxRecurrenceScore
Based on:		EvaluationResult
Concept:		TBD
Description:	"The Oncotype DX breast cancer test examines the activity of 21 genes in a patientâ€™s breast tumor tissue to provide personalized information for tailoring treatment based on the biology of their individual disease. The value is 0 to 100 indicates the estimated risk of recurrence with highest risk indicated by score > 31."
Value: 			Quantity with units UCUM#1
				Interpretation from OncotypeDXRiskScoreInterpretationVS
1..1			ref(Specimen)

EntryElement: 	TumorDimensions
Based on:		EvaluationResult
Concept:		MTH#C4086369
0..0			Value
				FindingCode is TBD#TBD
				EvaluationComponent
includes 0..1	TumorPrimaryDimensionSize
includes 0..1	TumorSecondaryDimensionSize
includes 0..1	SizeOfGrossTumorBed

		Element:		TumorPrimaryDimensionSize
		Description:	"The longest diameter of the primary tumor."
		Based on:		EvaluationComponent
		Concept:		TBD
		Value:			Quantity with units UCUM#mm		
		
		Element:		TumorSecondaryDimensionSize
		Description:	"The longest perpendicular diameter of the primary tumor."
		Based on:		EvaluationComponent
		Concept:		TBD
		Value:			Quantity with units UCUM#mm

		Element:		SizeOfGrossTumorBed
		Based on:		EvaluationComponent
		Concept:		TBD
		Description:	"The largest dimension of the gross tumor bed/fibrotic area."
		Value:			Quantity with units UCUM#mm


EntryElement: 	TumorMargins
Based on:		EvaluationResult
Concept:		MTH#C4086369
Description:	"The edge or border of the tissue removed in cancer surgery. The margin is described as negative or clean when the pathologist finds no cancer cells at the edge of the tissue, suggesting that all of the cancer has been removed. The margin is described as positive or involved when the pathologist finds cancer cells at the edge of the tissue, suggesting that all of the cancer has not been removed."
Value: 			CodeableConcept from PositiveNegativeIndeterminateVS
				FindingCode is TBD#TBD
				EvaluationComponent
includes 0..1	TumorMarginDescription
includes 0..1	Cellularity   // not sure this belongs here
includes 0..1	PercentageInSituCarcinoma   // not sure this belongs here
// Do we need to record the method? whether the result of imaging, or study of a removed tumor after lumpectomy?	

		Element:		TumorMarginDescription
		Concept:		TBD
		Based on:		EvaluationComponent
		Description:	"Description of the edge or border of tumor in situ by radiologist or of removed tumor by pathologist."
		Value:			CodeableConcept from TumorMarginDescriptionVS

		Element:		Cellularity
		Concept:		MTH#C4055283
		Based on:		EvaluationComponent
		Description:	"Percentage of cells in a sample that are cancerous"
		Value:			Quantity with units UCUM#%

		Element:		PercentageInSituCarcinoma
		Based on:		EvaluationComponent
		Concept:		TBD
		Description:	"The percentage of the cancer that is in situ, as opposed to invading other tissues."
		Value:			Quantity with units UCUM#%

	
EntryElement:	LymphaticInvolvement
Based on:		EvaluationResult
Concept:		MTH#C0746333
Description:	"Description of lymph nodes contain cancer cells."
Value:			CodeableConcept from PositiveNegativeIndeterminateVS
1..1			BodySite from LymphSystemSubdivisionVS 
				EvaluationComponent
includes 0..1 	LargestLymphNodeSize
includes 0..1 	NumberOfLymphNodesInvolved
includes 0..1 	DegreeOfLymphaticInvolvement

		Element:		LargestLymphNodeSize
		Based on:		EvaluationComponent
		Concept:		MTH#C1285847
		Description:	"The largest dimension of the largest lymph node invaded by cancer cells."
		Value: 			Quantity with units UCUM#mm
						
		Element:		NumberOfLymphNodesInvolved
		Based on:		EvaluationComponent
		Concept:		TBD
		Description:	"A count of lymph nodes invaded by cancer cells of those examined."
		Value:			Quantity with units UCUM#1

		Element:		DegreeOfLymphaticInvolvement
		Based on:		EvaluationComponent
		Concept:		TBD
		Description:	"Assessment of how much cancer is in a lymph node."
		Value:			CodeableConcept from DegreeOfLymphaticInvolvementVS



	Element: 		Ki-67LabelingIndex
	Based on:		EvaluationResult		
	Concept:		MTH#C4049944
	Description:	"Ki-67 is a protein phosphatase whose expression is strongly associated with cell proliferation and encoded by the MKI67 gene. The Ki67 labeling index is the fraction of Ki-67-positive cells to total cells in a tumor specimen and may be useful for determining prognosis with respect to survival and disease recurrence. The more positive cells there are, the more quickly they are dividing and forming new cells.	ReferenceRange: Low <10, Intermediate 10-20, >20 High"
	Value:		 	Quantity with units UCUM#%
					FindingCode is LNC#29593-1
					EvaluationComponent
	includes 0..1	PrimaryAntibody  //from Ki67AntibodyVS if covered

	Element:		S-PhaseFraction
	Based on:		EvaluationResult
	Concept:		MTH#C0812425
	Description: "An expression of the number of mitoses found in a stated number of cells. The S-phase fraction number tells you what percentage of cells in the tissue sample are in the process of copying their genetic information (DNA). This S-phase, short for synthesis phase, happens just before a cell divides into two new cells. ReferenceRange: Low <6, Intermediate 6-10, >10 High."
	Value:			Quantity with units UCUM#%
					FindingCode is LNC#29593-1

EntryElement:	GeneticVariant
Based on:		EvaluationResult
Concept:		MTH#C0678941
Description:	"Whether a subject carries a mutation in a particular gene."
Value:			CodeableConcept from PositiveNegativeIndeterminateVS
1..1			Focus_CodeableConcept from GeneIdentifierVS
				EvaluationComponent
includes 0..1	Refseq

			Element:		Refseq
			Based on:		EvaluationComponent
			Concept:		TBD
			Description:	"The Reference Sequence (RefSeq) collection provides a comprehensive, integrated, non-redundant, well-annotated set of sequences, including genomic DNA, transcripts, and proteins. RefSeq sequences form a foundation for medical, functional, and diversity studies. They provide a stable reference for genome annotation, gene identification and characterization, mutation and polymorphism analysis (especially RefSeqGene records), expression studies, and comparative analyses."
			Value: 			CodeableConcept from RefseqVS

EntryElement:	BreastCancerGeneticAnalysisPanel
Concept:		TBD
Based on:		EvaluationResult
Description:	"The status of genes known or suspected to play a role in breast cancer risk, for example, the tumor suppressor genes, BRCA1 and BRCA2."
				FindingCode is TBD#TBD
				Members.EvaluationTopic
includes 1..1	BRCA1Variant
includes 1..1	BRCA2Variant

	Element:		BRCA1Variant
	Concept:		TBD
	Based on:		GeneticVariant
	Description:	"Whether the patient has a mutation in the BRCA1 gene."
	Value:			CodeableConcept from PositiveNegativeIndeterminateVS
					Focus_CodeableConcept is HGNC#BRCA1Gene

	Element:		BRCA2Variant
	Concept:		TBD
	Based on:		GeneticVariant
	Description:	"Whether the patient has a mutation in the BRCA2 gene."
	Value:			CodeableConcept from PositiveNegativeIndeterminateVS
					Focus_CodeableConcept is HGNC#BRCA2Gene




/*
FHIR Genomics:
https://www.hl7.org/FHIR/2016Jan/obs-genetics-example3-bcr1%20and%20bcr2%20sequencing%20with%20FamilyHistory%20-1.json.html
https://www.hl7.org/FHIR/2016Jan/observation-genetics-cg-prf-1a.html
https://www.hl7.org/FHIR/2016Jan/observation-genetics.html
https://www.hl7.org/FHIR/2016Jan/obs-genetics-example2-germline.html
*/